ASH 2022 | Preventing relapse following BMT in ALL & AML
Michael Bishop, MD, University of Chicago, Chicago, IL, discusses the importance of finding therapies to prevent relapse in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) following bone marrow transplantation (BMT). Prof. Bishop explains that combining various immune-modifying modalities such as bispecific antibodies and CAR-T therapy can improve outcomes in relapsed/refractory (R/R) patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bristol Myers Squibb: Honoraria, Other: Travel support, Speakers Bureau; Novartis: Consultancy, Honoraria, Other: Travel support , Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; Agios: Consultancy, Honoraria, Other: Travel support, Speakers Bureau; Iovance: Consultancy; Bluebird Bio: Consultancy; WindMIL Therapeutics: Consultancy; Arcellx: Consultancy, Research Funding; Autolus: Consultancy, Research Funding; Immatics: Research Funding; Triumvira: Research Funding; Tmunity: Research Funding; Chimeric Therapeutics: Consultancy; Sanofi: Honoraria, Speakers Bureau; Sana Biotechnology: Consultancy; Servier: Speakers Bureau; ADC Therapeutics: Speakers Bureau; Celgene: Honoraria; Incyte: Honoraria, Other: Travel support , Speakers Bureau; Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel support, Research Funding, Speakers Bureau.
